Intellia Therapeutics’ (NTLA) Neutral Rating Reiterated at Wedbush

Wedbush reaffirmed their neutral rating on shares of Intellia Therapeutics (NASDAQ:NTLA) in a research report sent to investors on Thursday,RTT News reports. The brokerage currently has a $14.00 price objective on the stock.

NTLA has been the topic of several other research reports. JPMorgan Chase & Co. reduced their price target on shares of Intellia Therapeutics from $61.00 to $55.00 and set an “overweight” rating on the stock in a research report on Monday, August 12th. Evercore ISI upgraded shares of Intellia Therapeutics to a “strong-buy” rating in a research report on Friday, August 9th. Chardan Capital reduced their price target on shares of Intellia Therapeutics from $94.00 to $88.00 and set a “buy” rating on the stock in a research report on Thursday, October 24th. The Goldman Sachs Group reduced their price target on shares of Intellia Therapeutics from $31.00 to $20.00 and set a “neutral” rating on the stock in a research report on Friday, October 25th. Finally, Robert W. Baird cut their target price on shares of Intellia Therapeutics from $24.00 to $18.00 and set a “neutral” rating on the stock in a research report on Friday, October 25th. One equities research analyst has rated the stock with a sell rating, five have assigned a hold rating, eleven have assigned a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, Intellia Therapeutics presently has a consensus rating of “Moderate Buy” and an average price target of $58.00.

Intellia Therapeutics Stock Up 4.6 %

NTLA opened at $16.73 on Thursday. The firm’s 50-day simple moving average is $19.17 and its 200-day simple moving average is $22.23. Intellia Therapeutics has a twelve month low of $13.95 and a twelve month high of $34.87.

Intellia Therapeutics (NASDAQ:NTLA) last posted its earnings results on Thursday, November 7th. The company reported ($1.34) earnings per share for the quarter, topping the consensus estimate of ($1.37) by $0.03. The firm had revenue of $9.10 million during the quarter, compared to the consensus estimate of $8.28 million. During the same period in the previous year, the company posted ($1.38) EPS. The firm’s revenue for the quarter was down 24.1% compared to the same quarter last year. Equities analysts expect that Intellia Therapeutics will post -5.21 earnings per share for the current fiscal year.

Insider Activity at Intellia Therapeutics

In related news, CAO Michael P. Dube sold 2,012 shares of the stock in a transaction that occurred on Wednesday, October 2nd. The shares were sold at an average price of $19.01, for a total value of $38,248.12. Following the sale, the chief accounting officer now directly owns 47,012 shares in the company, valued at $893,698.12. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. 3.20% of the stock is currently owned by corporate insiders.

Institutional Trading of Intellia Therapeutics

A number of large investors have recently bought and sold shares of NTLA. Blue Trust Inc. increased its stake in Intellia Therapeutics by 1,664.3% during the 2nd quarter. Blue Trust Inc. now owns 1,482 shares of the company’s stock worth $33,000 after purchasing an additional 1,398 shares in the last quarter. EverSource Wealth Advisors LLC increased its stake in Intellia Therapeutics by 763.5% during the 2nd quarter. EverSource Wealth Advisors LLC now owns 1,753 shares of the company’s stock worth $39,000 after purchasing an additional 1,550 shares in the last quarter. Eastern Bank bought a new stake in Intellia Therapeutics during the 3rd quarter worth approximately $41,000. Values First Advisors Inc. bought a new stake in Intellia Therapeutics during the 3rd quarter worth approximately $54,000. Finally, First Horizon Advisors Inc. increased its stake in Intellia Therapeutics by 22.1% during the 2nd quarter. First Horizon Advisors Inc. now owns 2,604 shares of the company’s stock worth $58,000 after purchasing an additional 472 shares in the last quarter. 88.77% of the stock is owned by institutional investors.

Intellia Therapeutics Company Profile

Intellia Therapeutics, Inc, a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease.